New research suggests that a class of drugs called PARP inhibitors, designed to treat hereditary forms of ovarian and breast cancer, don't work the way we thought they did. It also paints a fuller picture of how they work, opening the door to improvements in next-generation drugs.
from Top Health News -- ScienceDaily https://ift.tt/2O8kTMp
No comments:
Post a Comment